Cochrane · systematic review · CD008418

Formoterol versus short‐acting beta‐agonists as relief medication for adults and children with asthma

Welsh, EJ, Cates, CJ · Cochrane Database of Systematic Reviews · 2010 · Cochrane Library

AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 4 · 66.7%Moderate 2 · 33.3%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Formoterol versus short‐acting beta2‐agonist as relief medication for asthma

Population: Patients with asthma
6 questions
OutcomeEffectEvidenceStatus / GRADE
Patients with an exacerbation requiring hospitalisation
Formoterol vs short‐acting beta2‐agonist
OR 0.84 [0.67, 1.04]7 studies · 22236 participantsModerate
Patients with an exacerbation requiring a course of oral corticosteroids
Formoterol vs short‐acting beta2‐agonist
OR 0.84 [0.77, 0.91]6 studies · 21591 participantsModerate
Downgraded: imprecision
Fatal serious adverse events (all‐cause)
Formoterol vs short‐acting beta2‐agonist
OR 1.08 [0.51, 2.3]5 studies · 21629 participantsLow
Downgraded: imprecision
Patients with a serious adverse event (all cause)
Formoterol vs short‐acting beta2‐agonist
OR 0.94 [0.81, 1.08]7 studies · 22538 participantsLow
Downgraded: imprecision
Patients with a serious adverse event (asthma related)
Formoterol vs short‐acting beta2‐agonist
OR 0.91 [0.72, 1.15]6 studies · 21986 participantsLow
Downgraded: imprecision
Withdrawals (any reason)
Formoterol vs short‐acting beta2‐agonist
OR 1.12 [1.02, 1.24]7 studies · 22541 participantsLow
Downgraded: imprecision, inconsistency